Paul Griffin, director of infectious diseases at Mater Health Services in Brisbane, said current-generation influenza vaccines are still very effective in preventing influenza transmission.
However, Dr. Griffin, who is also a member of the Vaccine Medical Advisory Board, said such vaccines could be even more effective.
“Current flu vaccines are very good and rely very much on flu vaccination every year,” he said.
“This is an additional option that some people may choose to adopt.”
Dr. Griffin said the approval of young children is timely, given the suggestion that this year’s flu season in Australia could be tough after the virus has been largely dormant for anti-COVID measures. I said there is.
“In the year of influenza outbreaks a few light-years later, another option is offered so that as many people as possible can be vaccinated,” he said.
Dr. Anderson waited for the results of the clinical trial until approval was obtained for the age group over 2 years old, but only minor and expected side effects such as pain at the injection site and redness were recorded, and he is now successful. He said he was. Mild headache.
The Flucelvax Quad will be excluded from the National Immune Program in 2022, but the company hopes to be eligible in the future, so it will have to be purchased personally for about $ 40 each.
Prior to 2020, more Australian children under the age of five were hospitalized for influenza than other vaccine-preventable illnesses, according to federal government data from public hospitals.
Of the children hospitalized for influenza, 10-15% needed intensive care and up to 84% of the hospitalized children were unvaccinated.
Australia-approved cell-based influenza vaccine for children over 2 years of age
Source link Australia-approved cell-based influenza vaccine for children over 2 years of age